Base de dados : MEDLINE
Pesquisa : E01.190 [Categoria DeCS]
Referências encontradas : 3275 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 328 ir para página                         

  1 / 3275 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743237
[Au] Autor:de Waal MM; Dekker JJM; Kikkert MJ; Kleinhesselink MD; Goudriaan AE
[Ad] Endereço:Department of Research, Arkin Mental Health Care, Klaprozenweg 111, 1033 NN, Amsterdam, The Netherlands. m.m.dewaal@amc.uva.nl.
[Ti] Título:Gender differences in characteristics of physical and sexual victimization in patients with dual diagnosis: a cross-sectional study.
[So] Source:BMC Psychiatry;17(1):270, 2017 Jul 25.
[Is] ISSN:1471-244X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients with substance use disorders and co-occurring mental health disorders are vulnerable to violent victimization. However, no evidence-based interventions are available to reduce patients' vulnerability. An exploration of the characteristics of physical and sexual violence can provide valuable information to support the development of interventions for these patients. This study aimed to examine gender differences in characteristics of violent victimization in patients with dual diagnosis. METHODS: In this cross-sectional survey study recent incidents of physical and sexual assault were examined with the Safety Monitor in 243 patients with dual diagnosis. Chi-square tests were used to examine gender differences in the prevalence of physical and sexual victimization. Fisher's exact tests and Fisher-Freeman-Halton exact tests were used to determine whether there were significant differences between victimized men and women with regard to perpetrators, locations, reporting to the police and speaking about the assault with others. RESULTS: There was no significant difference in the prevalence of physical violence in men (35%) and women (47%) with dual diagnosis. There was a significant association between gender of the victim and type of perpetrator (P < .001). Men were most often physically abused by a stranger or an acquaintance, whereas women were most frequently abused by an (ex)partner. Sexual violence was more prevalent in women (29%) compared to men (4%) (P < .001). Patients with dual diagnosis were unlikely to report incidents of physical abuse and sexual assault to the police and to speak about it with caregivers. CONCLUSIONS: Characteristics of physical violence are different for men and women with dual diagnosis. Women with dual diagnosis are more often victims of sexual violence compared to men. Interventions aimed at reducing patients' vulnerability for victimization should take gender differences into account.
[Mh] Termos MeSH primário: Vítimas de Crime/estatística & dados numéricos
Diagnóstico Duplo (Psiquiatria)
Delitos Sexuais/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
Estudos Transversais
Feminino
Seres Humanos
Masculino
Países Baixos/epidemiologia
Prevalência
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores Sexuais
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1186/s12888-017-1413-0


  2 / 3275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29355909
[Au] Autor:Temmingh HS; Williams T; Siegfried N; Stein DJ
[Ad] Endereço:Department of Psychiatry and Mental Health, University of Cape Town, Valkenberg Hospital, Private Bage X1, Cape Town, Western Cape, South Africa, 7935.
[Ti] Título:Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
[So] Source:Cochrane Database Syst Rev;1:CD011057, 2018 Jan 22.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). Dual diagnosis can have an adverse effect on treatment and prognosis of SMI. OBJECTIVES: To evaluate the effects of risperidone compared to treatment with other antipsychotics (first-generation and other second-generation antipsychotics) used in people with serious mental illness and co-occurring substance misuse. SEARCH METHODS: On 6 January 2016 and 9 October 2017, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (including trial registers). SELECTION CRITERIA: We selected randomised trials of risperidone versus any other antipsychotic in people with SMI and substance abuse (dual diagnosis). We included trials meeting our inclusion criteria and reporting useable data. We excluded trials that either did not meet our inclusion criteria or met our inclusion criteria but did not report any useable data. DATA COLLECTION AND ANALYSIS: We independently inspected citations and selected studies. For included studies, we independently extracted data and appraised study quality. For binary outcomes we calculated the risk ratios (RRs) and their 95% confidence intervals. For continuous outcomes we calculated the mean differences (MDs) and their 95% confidence intervals. We pooled data using random-effects meta-analyses and assessed the quality of evidence, creating a 'Summary of findings' table using the GRADE approach. MAIN RESULTS: We identified eight randomised trials containing a total of 1073 participants with SMI and co-occurring substance misuse. Seven of these contributed useable data to the review. There was heterogeneity in trial design and measurement. Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone. Few trials compared risperidone with first-generation agents. Few trials examined participants with a dual diagnosis from the outset and most trials only contained separate analyses of subgroups with a dual diagnosis or were secondary data analyses of subgroups of people with a dual diagnosis from existing larger trials.For risperidone versus clozapine we found no clear differences between these two antipsychotics in the reduction of positive psychotic symptoms (1 randomised controlled trial (RCT), n = 36, mean difference (MD) 0.90, 95% CI -2.21 to 4.01, very low quality evidence), or reduction in cannabis use (1 RCT, n = 14, risk ratio (RR) 1.00, 95% CI 0.30 to 3.35, very low quality evidence), improvement in subjective well-being (1 RCT, n = 36, MD -6.00, 95% CI -14.82 to 2.82, very low quality evidence), numbers discontinuing medication (1 RCT, n = 36, RR 4.05, 95% CI 0.21 to 78.76, very low quality evidence), extrapyramidal side-effects (2 RCTs, n = 50, RR 2.71, 95% CI 0.30 to 24.08; I² = 0%, very low quality evidence), or leaving the study early (2 RCTs, n = 45, RR 0.49, 95% CI 0.10 to 2.51; I² = 34%, very low quality evidence). Clozapine was associated with lower levels of craving for cannabis (1 RCT, n = 28, MD 7.00, 95% CI 2.37 to 11.63, very low quality evidence).For risperidone versus olanzapine we found no clear differences in the reduction of positive psychotic symptoms (1 RCT, n = 37, MD -1.50, 95% CI -3.82 to 0.82, very low quality evidence), reduction in cannabis use (1 RCT, n = 41, MD 0.40, 95% CI -4.72 to 5.52, very low quality evidence), craving for cannabis (1 RCT, n = 41, MD 5.00, 95% CI -4.86 to 14.86, very low quality evidence), parkinsonism (1 RCT, n = 16, MD -0.08, 95% CI -1.21 to 1.05, very low quality evidence), or leaving the study early (2 RCT, n = 77, RR 0.68, 95% CI 0.34 to 1.35; I² = 0%, very low quality evidence).For risperidone versus perphenazine, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 281, RR 1.05, 95% CI 0.92 to 1.20, low-quality evidence).For risperidone versus quetiapine, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 294, RR 0.96, 95% CI 0.86 to 1.07, low-quality evidence).For risperidone versus ziprasidone, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 240, RR 0.96, 95% CI 0.85 to 1.10, low-quality evidence).For many comparisons, important outcomes were missing; and no data were reported in any study for metabolic disturbances, global impression of illness severity, quality of life or mortality. AUTHORS' CONCLUSIONS: There is not sufficient good-quality evidence available to determine the effects of risperidone compared with other antipsychotics in people with a dual diagnosis. Few trials compared risperidone with first-generation agents, leading to limited applicability to settings where access to second-generation agents is limited, such as in low- and middle-income countries. Moreover, heterogeneity in trial design and measurement of outcomes precluded the use of many trials in our analyses. Future trials in this area need to be sufficiently powered but also need to conform to consistent methods in study population selection, use of measurement scales, definition of outcomes, and measures to counter risk of bias. Investigators should adhere to CONSORT guidelines in the reporting of results.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Transtornos Mentais/tratamento farmacológico
Risperidona/uso terapêutico
Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico
[Mh] Termos MeSH secundário: Benzodiazepinas/uso terapêutico
Clozapina/uso terapêutico
Diagnóstico Duplo (Psiquiatria)
Seres Humanos
Pacientes Desistentes do Tratamento/estatística & dados numéricos
Perfenazina/uso terapêutico
Piperazinas/uso terapêutico
Fumarato de Quetiapina/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Esquizofrenia/tratamento farmacológico
Transtornos Relacionados ao Uso de Substâncias/psicologia
Tiazóis/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Piperazines); 0 (Thiazoles); 12794-10-4 (Benzodiazepines); 2S3PL1B6UJ (Quetiapine Fumarate); 6UKA5VEJ6X (ziprasidone); FTA7XXY4EZ (Perphenazine); J60AR2IKIC (Clozapine); L6UH7ZF8HC (Risperidone); N7U69T4SZR (olanzapine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180123
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD011057.pub2


  3 / 3275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28693877
[Au] Autor:Sorsa M; Greacen T; Lehto J; Åstedt-Kurki P
[Ad] Endereço:Pirkanmaa Hospital District, Child Psychiatry, Tampere, Finland; University of Tampere, Faculty of Social Sciences, Lääkärinkatu 1, 33014 University of Tampere, Finland. Electronic address: minna.sorsa@staff.uta.fi.
[Ti] Título:A Qualitative Study of Barriers to Care for People With Co-Occurring Disorders.
[So] Source:Arch Psychiatr Nurs;31(4):399-406, 2017 Aug.
[Is] ISSN:1532-8228
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The present qualitative study used face-to-face and telephone interviews with service providers in the Tampere area in Finland to describe the provider viewpoint on barriers to care for people with co-occurring disorders. The core barrier concerns the definition and understanding of the problems: client and professional perspectives often differ, and both can be out of step with what the care system actually proposes. Professionals need to take into account contexts with potentially multiple barriers to care. Providers in each local area should examine possible barriers and find solutions together, integrating the client perspective at each step in the process.
[Mh] Termos MeSH primário: Atitude do Pessoal de Saúde
Diagnóstico Duplo (Psiquiatria)
Acesso aos Serviços de Saúde
[Mh] Termos MeSH secundário: Finlândia
Seres Humanos
Entrevistas como Assunto
Transtornos Mentais/terapia
Serviços de Saúde Mental/utilização
Pesquisa Qualitativa
Transtornos Relacionados ao Uso de Substâncias/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:170712
[St] Status:MEDLINE


  4 / 3275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28686107
[Au] Autor:Regnart J; Truter I; Meyer A
[Ad] Endereço:a Drug Utilization Research Unit (DURU), Department of Pharmacy , Nelson Mandela Metropolitan University , Port Elizabeth , South Africa.
[Ti] Título:Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder, mood disorder and Substance Use Disorder.
[So] Source:Expert Rev Pharmacoecon Outcomes Res;17(3):275-282, 2017 Jun.
[Is] ISSN:1744-8379
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Co-occurring disorders (CODs) describe a Substance Use Disorder (SUD) accompanied by a comorbid psychiatric disorder. Attention-Deficit/Hyperactivity Disorder (ADHD) and mood disorders are common CODs with high prevalence rates in SUD populations. It is proposed that literature on a tri-condition presentation of ADHD, mood disorder and SUD is limited. Areas covered: A literature search was conducted using a keyword search on EBSCOhost. Initially 2 799 records were identified, however, only two articles included all three conditions occurring concurrently in individuals. CODs constitute a major concern due to their overarching burden on society as a whole. Diagnosis and treatment of such patients is challenging. There is evidence that dysfunction of dopamine in the brain reward circuitry impacts the development or symptomology of all three disorders. Disparity exists regarding whether ADHD or mood disorders are greater modifiers for increased SUD severity. However, it has been reported that poor functional capacity may have a greater influence than comorbidities on SUD development. Expert commentary: Challenges exist which confound the clear distinction of CODs, however, with greater emergence of adult ADHD its screening in SUD populations should become standard practice to establish data on multi-condition presentations with the ultimate goal of improving clinical outcomes.
[Mh] Termos MeSH primário: Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia
Transtornos do Humor/epidemiologia
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
[Mh] Termos MeSH secundário: Animais
Transtorno do Deficit de Atenção com Hiperatividade/fisiopatologia
Transtorno do Deficit de Atenção com Hiperatividade/terapia
Encéfalo/metabolismo
Encéfalo/fisiopatologia
Diagnóstico Duplo (Psiquiatria)
Dopamina/metabolismo
Seres Humanos
Transtornos do Humor/fisiopatologia
Transtornos do Humor/terapia
Prevalência
Recompensa
Índice de Gravidade de Doença
Transtornos Relacionados ao Uso de Substâncias/fisiopatologia
Transtornos Relacionados ao Uso de Substâncias/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE
[do] DOI:10.1080/14737167.2017.1351878


  5 / 3275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28327175
[Au] Autor:Polimanti R; Agrawal A; Gelernter J
[Ad] Endereço:Department of Psychiatry, Yale School of Medicine and VA CT Healthcare Center, West Haven, CT, USA. renato.polimanti@yale.edu.
[Ti] Título:Schizophrenia and substance use comorbidity: a genome-wide perspective.
[So] Source:Genome Med;9(1):25, 2017 Mar 21.
[Is] ISSN:1756-994X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Dual diagnosis with substance use disorders (SUDs) consistently contributes to the premature mortality and increased disability observed in schizophrenia. Large genome-wide association studies are providing the information needed to investigate the genetic architecture of psychiatric disorders. Here, we discuss recent genetic investigations of dual diagnosis (i.e., schizophrenia plus a SUD) and how these findings can inform public health messages.
[Mh] Termos MeSH primário: Esquizofrenia/genética
Transtornos Relacionados ao Uso de Substâncias/genética
[Mh] Termos MeSH secundário: Diagnóstico Duplo (Psiquiatria)
Estudo de Associação Genômica Ampla
Seres Humanos
Esquizofrenia/complicações
Esquizofrenia/diagnóstico
Esquizofrenia/etiologia
Transtornos Relacionados ao Uso de Substâncias/complicações
Transtornos Relacionados ao Uso de Substâncias/diagnóstico
Transtornos Relacionados ao Uso de Substâncias/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE
[do] DOI:10.1186/s13073-017-0423-3


  6 / 3275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28317503
[Au] Autor:Isgro M; Doran N; Heffner JL; Wong E; Dinh E; Tibbs J; Russell K; Bittner T; Wehrle C; Worley MJ; Anthenelli RM
[Ad] Endereço:Pacific Treatment and Research Center (Pac-TARC), San Diego Veterans Affairs Healthcare System, San Diego, California.
[Ti] Título:Type A/Type B Alcoholism Predicts Differential Response to Topiramate in a Smoking Cessation Trial in Dually Diagnosed Men.
[So] Source:J Stud Alcohol Drugs;78(2):232-240, 2017 Mar.
[Is] ISSN:1938-4114
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Babor's A/B typology characterizes alcohol-dependence subtypes, which differ across multiple defining variables; however, differences in cigarette smoking and cessation between these subtypes have not been previously investigated. Topiramate reduces heavy drinking and has separately been found to help non-alcohol-dependent individuals quit smoking. This study tested the hypothesis that topiramate's effects on smoking would be moderated by alcohol-dependence subtype, and explored craving as a mediator of this response. METHOD: One hundred twenty-nine abstinent alcohol-dependent outpatient male smokers participated in this 12-week, randomized controlled trial comparing topiramate (maximum dosage 200 mg/day) with placebo, both with brief counseling, for smoking cessation. Participants were followed for 24 weeks following end of treatment. RESULTS: Of the 125 participants with sufficient subtyping data, k-means cluster analysis categorized 52 (42%) as Type A alcoholics and 73 (58%) as Type B. Types A and B did not differ on baseline smoking characteristics, urges to smoke, or smoking consequence scores. Longitudinal mixed-effects regression indicated that the effect of treatment on smoking was moderated by the Type × Time interaction. Specifically, during the nontreatment follow-up phase, Type B's treated with topiramate had relative suppressed levels of smoking compared with placebo-treated Type B's. This moderating effect of the Type × Time interaction was mediated by intention to smoke and craving related to relief of negative affect. CONCLUSIONS: Type B alcoholics demonstrated suppressed levels of smoking in response to topiramate treatment as compared with placebo, but only during the nontreatment follow-up phase. This effect was mediated, in part, through intention to smoke and craving to smoke to relieve negative affect. Our findings extend other studies demonstrating a differential medication response by alcoholism subtype.
[Mh] Termos MeSH primário: Alcoolismo/psicologia
Frutose/análogos & derivados
Abandono do Hábito de Fumar/métodos
Fumar/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Fissura
Diagnóstico Duplo (Psiquiatria)
Método Duplo-Cego
Frutose/administração & dosagem
Seres Humanos
Masculino
Meia-Idade
Pacientes Ambulatoriais
Fumar/psicologia
Abandono do Hábito de Fumar/psicologia
Tabagismo/psicologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0H73WJJ391 (topiramate); 30237-26-4 (Fructose)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171029
[Lr] Data última revisão:
171029
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170321
[St] Status:MEDLINE


  7 / 3275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28296627
[Au] Autor:Lopes-Rosa R; Kessler FP; Pianca TG; Guimarães L; Ferronato P; Pagnussat E; Moura H; Pechansky F; von Diemen L
[Ad] Endereço:a Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS) , Porto Alegre , RS , Brazil.
[Ti] Título:Predictors of early relapse among adolescent crack users.
[So] Source:J Addict Dis;36(2):136-143, 2017 Apr-Jun.
[Is] ISSN:1545-0848
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Relapse is associated with a poor prognosis among drug users. Crack cocaine users are more prone to severe dependence because of the intensity of use. Additionally, initiating drug use during adolescence worsens users' prognosis due to the increased rates of impulsivity and other risk behaviors. This study aimed to identify the predictors of early relapse among adolescent crack users discharged from inpatient treatment. A cohort study was conducted with 89 psychiatric inpatients aged 12-17 years from two different hospitals in southern Brazil who met the criteria for crack abuse or dependence. Demographic data, substance use disorders, psychiatric comorbidities, and crack consumption profile were assessed during hospitalization using the Teen Addiction Severity Index, Schedule for Affective Disorders and Schizophrenia for School Age Children-Present and Lifetime, and Crack Consumption Profile. Participants were re-assessed at 1 and 3 months after hospital discharge to determine their crack cocaine use based on self-report, family/caregiver information, and urine tests, whenever possible. There were extremely high rates of relapse (valid percent) in the first and third months, 65.9 and 86.4%, respectively. Statistically significant associations were observed between relapse in the first month and length of cocaine/crack cocaine use, and length of hospital stay. Data at 3 months were not analyzed because of the small number of patients who did not relapse. The high rates and significant associations found in this study suggest that intensive outpatient treatment strategies targeting this population should be developed and implemented to prevent early relapse after detoxification. One of the possible approaches, based on recent studies, might explore motivation as a strategy to reduce the rate of early relapse.
[Mh] Termos MeSH primário: Transtornos Relacionados ao Uso de Cocaína/epidemiologia
Transtornos Mentais/epidemiologia
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Comportamento do Adolescente
Brasil/epidemiologia
Criança
Transtornos Relacionados ao Uso de Cocaína/psicologia
Comorbidade
Cocaína Crack
Diagnóstico Duplo (Psiquiatria)/estatística & dados numéricos
Feminino
Seres Humanos
Tempo de Internação/estatística & dados numéricos
Masculino
Recidiva
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Crack Cocaine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1080/10550887.2017.1295670


  8 / 3275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28262143
[Au] Autor:Subodh BN; Hazari N; Elwadhi D; Basu D
[Ad] Endereço:Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India. Electronic address: drsubodhbn2002@gmail.com.
[Ti] Título:Prevalence of dual diagnosis among clinic attending patients in a de-addiction centre of a tertiary care hospital.
[So] Source:Asian J Psychiatr;25:169-174, 2017 Feb.
[Is] ISSN:1876-2026
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: Indian research on dual diagnosis is mostly on prevalence of co-morbidity in a particular type of substance use disorder or psychiatric disorder. They were not on overall prevalence of dual diagnosis in a clinical sample. The study aims to assess prevalence of dual diagnosis among first time visitors to a tertiary care deaddiction centre. METHODOLOGY: The study participants were recruited using computer-generated random number table from 10th Apr 2013 to 28 June 2013 from a deaddiction centre in North India. Psychiatric diagnosis was done by qualified psychiatrist and confirmed by Mini International Neuropsychiatric Interview (M.I.N.I.). RESULTS: One seventy nine participants were recruited during the study period. The prevalence of dual diagnosis was 58 (32.4%). Affective disorder group 22 (12.3%) is the most common group followed by anxiety disorders group 20 (11.2%) and psychotic disorder group 9 (5.0%). Duration of use and dependence (in months) of alcohol, opioids, and nicotine was shorter and of cannabis and benzodiazepines was longer in dual diagnosis group compared to non dual diagnosis group. CONCLUSIONS: This study screened the largest number of substance use disorders patients visiting a tertiary care centre in India using a sound methodology. The study reported that nearly one third of substance use disorder patients are cases of dual diagnosis. The prevalence reported in our study is lower than reported in some western hospital based and community based studies.
[Mh] Termos MeSH primário: Transtornos de Ansiedade/epidemiologia
Transtornos do Humor/epidemiologia
Transtornos Psicóticos/epidemiologia
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Comorbidade
Diagnóstico Duplo (Psiquiatria)/estatística & dados numéricos
Seres Humanos
Índia/epidemiologia
Masculino
Meia-Idade
Pacientes Ambulatoriais
Prevalência
Centros de Atenção Terciária/estatística & dados numéricos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170314
[Lr] Data última revisão:
170314
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170307
[St] Status:MEDLINE


  9 / 3275 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28252507
[Au] Autor:Balhara YP; Kuppili PP; Gupta R
[Ad] Endereço:Yatan Pal Singh Balhara, MD, DNB (Psychiatry), MNAMS, Department of Psychiatry, National Drug Dependence Treatment Centre, WHO Collaborating Centre on Substance Abuse, All India Institute of Medical Sciences, New Delhi; and Regional Mentor, International Programme in Addiction Studies Master of Science in Addiction Studies King's College London, UK; University of Adelaide, Australia; Virginia Commonwealth University.Pooja Patnaik Kuppili, MD (Psychiatry) and Rishab Gupta, MD (Psychiatry), Department of Psychiatry, All India Institute of Medical Sciences, New Delhi.
[Ti] Título:Neurobiology of Comorbid Substance Use Disorders and Psychiatric Disorders: Current State of Evidence.
[So] Source:J Addict Nurs;28(1):11-26, 2017 Jan/Mar.
[Is] ISSN:1548-7148
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: "Dual disorder" or "dual diagnosis" refers to the co-occurrence of substance use disorder and psychiatric disorders. Prospective studies have shown that treatment outcomes, such as symptom levels, hospitalization rates, housing stability, and functional status, are worse among the patients with dual disorders as compared with those who have either of these disorders. OBJECTIVES: The current article is aimed at reviewing the current state of evidence on neurobiology of dual disorders. Given the high prevalence of co-occurrence of substance use disorder and psychiatric disorders, it is important to explore the various facets of this association. The current review assimilates the information on neurobiological research on dual disorders and helps the readers gain insights into the current understanding on this theme. METHODS: The electronic database of PubMed was searched for relevant publications. RESULTS: The studies included in the review belonged to various domains of neurobiology including neuropathology, structural neuroimaging, functional neuroimaging, genetics, neurochemicals/neuroreceptors, and neuroendocrinology. Forty studies were included in the review. CONCLUSIONS: Most of the issues related to the neurobiology of dual disorders remain inadequately studied. However, the current evidence suggests that the individuals with co-occurring disorders are likely to differ from those with either substance use disorders or psychiatric disorders alone on various neurobiological aspects. Hence, it is imperative to systematically study the various neurobiological aspects of dual disorders in the future.
[Mh] Termos MeSH primário: Encéfalo/fisiopatologia
Transtornos Mentais/fisiopatologia
Neuroimagem/métodos
Transtornos Relacionados ao Uso de Substâncias/fisiopatologia
[Mh] Termos MeSH secundário: Encéfalo/diagnóstico por imagem
Encéfalo/patologia
Diagnóstico Duplo (Psiquiatria)
Seres Humanos
Transtornos Mentais/diagnóstico por imagem
Transtornos Mentais/patologia
Transtornos Relacionados ao Uso de Substâncias/diagnóstico por imagem
Transtornos Relacionados ao Uso de Substâncias/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170707
[Lr] Data última revisão:
170707
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:170303
[St] Status:MEDLINE
[do] DOI:10.1097/JAN.0000000000000155


  10 / 3275 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28234723
[Au] Autor:Gaudiano BA; Wenze SJ; Weinstock LM; Tezanos KM; Miller IW
[Ad] Endereço:*Department of Psychiatry & Human Behavior, Warren Alpert Medical School of Brown University; †Psychosocial Research, Butler Hospital, Providence, RI; and ‡Department of Psychology, Lafayette College, Easton, PA.
[Ti] Título:Valued Living and Its Relationship to Medication Adherence in Patients with Bipolar and Comorbid Substance Use Disorders.
[So] Source:J Nerv Ment Dis;205(3):178-181, 2017 Mar.
[Is] ISSN:1539-736X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bipolar disorder with comorbid substance abuse is associated with high rates of treatment nonadherence. Adherence interventions developed to date have had mixed effects in this population. Valued living (i.e., the consistency between a patient's personal values and daily actions) represents a potentially useful treatment target that may improve adherence. We investigated the relationship between valued living, medication adherence, symptoms, and functioning in a sample of 39 patients diagnosed with bipolar disorder and a comorbid substance use disorder. Results showed that greater values-action consistency explained a unique amount of variance (R change = 15.2%) in medication adherence even after controlling for symptom severity, functional impairment, and other reported reasons for nonadherence. Drug use and treatment beliefs also predicted nonadherence. Findings suggest that valued living should be investigated further as a potentially malleable treatment target in future adherence intervention research.
[Mh] Termos MeSH primário: Transtorno Bipolar/psicologia
Conhecimentos, Atitudes e Prática em Saúde
Adesão à Medicação/psicologia
Valores Sociais
Transtornos Relacionados ao Uso de Substâncias/psicologia
[Mh] Termos MeSH secundário: Adulto
Transtorno Bipolar/epidemiologia
Comorbidade
Diagnóstico Duplo (Psiquiatria)
Feminino
Seres Humanos
Masculino
Adesão à Medicação/estatística & dados numéricos
Meia-Idade
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170529
[Lr] Data última revisão:
170529
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170225
[St] Status:MEDLINE
[do] DOI:10.1097/NMD.0000000000000533



página 1 de 328 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde